In the realm of ear health, accurate diagnosis is crucial for effective treatment, especially when dealing with conditions that can lead to hearing loss.
Gilead stops last PhIII of CD47 drug, citing FDA hold, higher risk of death in treatment arm
Gilead discontinued its remaining Phase III study of magrolimab, an anti-CD47 antibody that the company was testing for acute myeloid leukemia and its precursor disease,
February 8, 2024